Abstract: Objective Coexisting ALK and BRAF mutations are extremely rare in nonsmall cell lung cancer（NSCLC），and effective treatment options are not yet supported by clinical cases and data，thus this report is expected to provide a clinical reference for treating this group of patients. Methods To report a case of advanced lung adenocarcinoma in an 86-year-old female with coexisting ALK fusion and BRAF mutation，who was treated with dabrafenib plus trametinib. Results In our case，the patient achieved partial response （PR） after the treatment， and no serious adverse reactions were observed during the treatment. Conclusion With the rapid development of gene detection technology and biotargeted drugs，the survival rate and life quality of patients with advanced NSCLC have been improved. This patient showed definite efficacy for dabrafenib plus trametinib， which provides a significant reference to the clinical diagnosis and treatment of NSCLC with ALK and BRAF mutations.

Key words: non-small cell lung cancer（NSCLC）, ALK fusion, BRAF mutation, targeted therapy, case reports